Literature DB >> 1332985

The effect of 17 alpha-hydroxyprogesterone caproate/oestradiol valerate on the development and outcome of early pregnancies following in vitro fertilization and embryo transfer: a prospective and randomized controlled trial.

G Prietl1, K Diedrich, H H van der Ven, J Luckhaus, D Krebs.   

Abstract

A prospective and randomized study was performed to investigate the effect of supportive hormones on the development and outcome of early pregnancies following in vitro fertilization and embryo transfer. Immediately after pregnancies were confirmed endocrinologically on day 15 after oocyte collection, 17 alpha-hydroxyprogesterone caproate and oestradiol valerate (PC/EV) was administered to half of the patients in a randomly controlled trial. One group received supportive treatment until the twelfth week of gestation, whereas the other group received no treatment at all. Both groups were followed up by measurements of serum levels of human chorionic gonadotrophin (HCG), oestradiol and progesterone every three days until day 35, when a first ultrasound examination was carried out to confirm fetal vitality. Subsequently, pregnancies were monitored sonographically at regular intervals. In cases of miscarriage, dilatation and curettage was performed and histology analysed. A total of 120 pregnant patients entered the study: 55 of them received hormone treatment and 65 patients were controls. Within the treatment group 48 (89%) clinically ongoing pregnancies were observed, five (9%) miscarriages occurred after the seventh week of gestation and one preclinical pregnancy was noted. In the control group, 38 (59%) ongoing pregnancies were observed, nine (14%) miscarriages occurred and 17 (27%) preclinical pregnancies were recorded. Two ectopic pregnancies, one in each group, were excluded from evaluation. A significantly higher percentage of pregnancies were intact at 7 weeks of gestation after treatment with PC/EV (p less than or equal to 0.01).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1332985     DOI: 10.1093/humrep/7.suppl_1.1

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  8 in total

Review 1.  The optimal duration of progesterone supplementation in pregnant women after IVF/ICSI: a meta-analysis.

Authors:  Xi-Ru Liu; Hua-Qiao Mu; Qi Shi; Xiao-Qiu Xiao; Hong-Bo Qi
Journal:  Reprod Biol Endocrinol       Date:  2012-12-13       Impact factor: 5.211

2.  Progestogen for preventing miscarriage in women with recurrent miscarriage of unclear etiology.

Authors:  David M Haas; Taylor J Hathaway; Patrick S Ramsey
Journal:  Cochrane Database Syst Rev       Date:  2019-11-20

3.  Progestogens for preventing miscarriage: a network meta-analysis.

Authors:  Adam J Devall; Argyro Papadopoulou; Marcelina Podesek; David M Haas; Malcolm J Price; Arri Coomarasamy; Ioannis D Gallos
Journal:  Cochrane Database Syst Rev       Date:  2021-04-19

Review 4.  Combined oestrogen and progesterone for preventing miscarriage.

Authors:  Chi Eung Danforn Lim; Karen K W Ho; Nga Chong Lisa Cheng; Felix W S Wong
Journal:  Cochrane Database Syst Rev       Date:  2013-09-25

5.  Care prior to and during subsequent pregnancies following stillbirth for improving outcomes.

Authors:  Aleena M Wojcieszek; Emily Shepherd; Philippa Middleton; Zohra S Lassi; Trish Wilson; Margaret M Murphy; Alexander Ep Heazell; David A Ellwood; Robert M Silver; Vicki Flenady
Journal:  Cochrane Database Syst Rev       Date:  2018-12-17

6.  A 10-year follow-up on the practice of luteal phase support using worldwide web-based surveys.

Authors:  Gon Shoham; Milton Leong; Ariel Weissman
Journal:  Reprod Biol Endocrinol       Date:  2021-01-26       Impact factor: 5.211

7.  Progestogen for preventing miscarriage in women with recurrent miscarriage of unclear etiology.

Authors:  David M Haas; Taylor J Hathaway; Patrick S Ramsey
Journal:  Cochrane Database Syst Rev       Date:  2018-10-08

8.  Progestogen for treating threatened miscarriage.

Authors:  Hayfaa A Wahabi; Amel A Fayed; Samia A Esmaeil; Khawater Hassan Bahkali
Journal:  Cochrane Database Syst Rev       Date:  2018-08-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.